This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
NRC's Q2 Earnings Rise Y/Y on Cost Control and TRCV Growth
by Zacks Equity Research
National Research's Q2 adjusted earnings improved year over year on cost control and TRCV gains, but a one-time executive expense weighed on margins.
NRC Q1 Earnings Dip Y/Y Amid Rising Interest Costs, Shares Up 13%
by Zacks Equity Research
National Research reports a year-over-year decline in Q1 earnings, pressured by rising interest costs, declining revenues, and higher debt levels amid ongoing sales force expansion.
The Zacks Analyst Blog Philip Morris, Booking Holdings, Anheuser-Busch InBev, Elite Pharmaceuticals and National Research
by Zacks Equity Research
Philip Morris, Booking Holdings, Anheuser-Busch InBev, Elite Pharmaceuticals and National Research are included in this Analyst Blog.
Top Stock Reports for Philip Morris, Booking Holdings & Anheuser-Busch
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Philip Morris International Inc. (PM), Booking Holdings Inc. (BKNG) and Anheuser-Busch InBev SA/NV (BUD), as well as two micro-cap stocks Elite Pharmaceuticals, Inc. (ELTP) and National Research Corp. (NRC).
National Research's Q4 Earnings Drop Y/Y, Stock Falls 9%
by Zacks Equity Research
NRC's Q4 EPS drops to 28 cents despite revenue growth, hit by rising costs and higher interest expenses.
Zacks Initiates Coverage of NRC Health With Neutral Recommendation
by Debasmita Chatterjee
Discover why Zacks has given NRC Health a "Neutral" rating, being the first on Wall Street to initiate coverage on the stock. Dive into the company's AI innovations, strategic partnerships, and financial resilience, along with the challenges of revenue declines, rising debt and stiff competition.
National Research (NRC) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
National Research (NRC) delivered earnings and revenue surprises of 11.54% and 3.81%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: National Research (NRC) Q2 Earnings Expected to Decline
by Zacks Equity Research
National Research (NRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
National Research (NRC) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
National Research (NRC) delivered earnings and revenue surprises of 7.69% and -8.74%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?